Table 1 Patients characteristics

Age

  < 70

535 (68.2%)

10051 (63.7%)

42718 (56.9%)

53304 (58.2%)

  ≥ 70

250 (31.8%)

5725 (36.3%)

32356 (43.1%)

38331 (41.8%)

Sex

 Female

331 (42.2%)

7859 (49.8%)

33645 (44.8%)

41835 (45.7%)

 Male

454 (57.8%)

7917 (50.2%)

41429 (55.2%)

49800 (54.3%)

Race

 Black

102 (13.0%)

1451 (9.2%)

9651 (12.9%)

11204 (12.2%)

 Others

31 (3.9%)

719 (4.6%)

6945 (9.3%)

7695 (8.4%)

 White

652 (83.1%)

13606 (86.2%)

58478 (77.9%)

72736 (79.4%)

Stage

 III

228 (29.0%)

4744 (30.1%)

24316 (32.4%)

29288 (32.0%)

 IV

557 (71.0%)

11032 (69.9%)

50758 (67.6%)

62347 (68.0%)

T stage

 T0

11 (1.4%)

207 (1.3%)

624 (0.8%)

842 (0.9%)

 T1

113 (14.4%)

1667 (10.6%)

8685 (11.6%)

10465 (11.4%)

 T2

220 (28.0%)

3895 (24.7%)

20667 (27.5%)

24782 (27.0%)

 T3

185 (23.6%)

3523 (22.3%)

19624 (26.1%)

23332 (25.5%)

 T4

256 (32.6%)

6484 (41.1%)

25474 (33.9%)

32214 (35.2%)

N stage

 N0

155 (19.7%)

1572 (10.0%)

14948 (19.9%)

16675 (18.2%)

 N1

69 (8.8%)

949 (6.0%)

6363 (8.5%)

7381 (8.1%)

 N2

395 (50.3%)

9431 (59.8%)

38767 (51.6%)

48593 (53.0%)

 N3

166 (21.1%)

3824 (24.2%)

14996 (20.0%)

18986 (20.7%)

M stage

 M0

228 (29.0%)

4744 (30.1%)

24316 (32.4%)

29288 (32.0%)

 M1

557 (71.0%)

11032 (69.9%)

50758 (67.6%)

62347 (68.0%)

Bilaterality

 No

778 (99.1%)

15654 (99.2%)

74032 (98.6%)

90464 (98.7%)

 Yes

7 (0.9%)

122 (0.8%)

1042 (1.4%)

1171 (1.3%)

Bone metastasis

 No

606 (77.2%)

11830 (75.0%)

55663 (74.1%)

68099 (74.3%)

 Yes

179 (22.8%)

3946 (25.0%)

19411 (25.9%)

23536 (25.7%)

Liver metastasis

 No

617 (78.6%)

11231 (71.2%)

66924 (89.1%)

78772 (86.0%)

 Yes

168 (21.4%)

4545 (28.8%)

8150 (10.9%)

12863 (14.0%)

Lung metastasis

 No

670 (85.4%)

13482 (85.5%)

58797 (78.3%)

72949 (79.6%)

 Yes

115 (14.6%)

2294 (14.5%)

16277 (21.7%)

18686 (20.4%)

Brain metastasis

 No

564 (71.8%)

12843 (81.4%)

61145 (81.4%)

74552 (81.4%)

 Yes

221 (28.2%)

2933 (18.6%)

13929 (18.6%)

17083 (18.6%)

Surgery

 No/Unknown

680 (86.6%)

15575 (98.7%)

68677 (91.5%)

84932 (92.7%)

 Yes

105 (13.4%)

201 (1.3%)

6397 (8.5%)

6703 (7.3%)

Chemotherapy

 No/Unknown

228 (29.0%)

2914 (18.5%)

27863 (37.1%)

31005 (33.8%)

 Yes

557 (71.0%)

12862 (81.5%)

47211 (62.9%)

60630 (66.2%)

Radiation

 No/Unknown

333 (42.4%)

7143 (45.3%)

35311 (47.0%)

42787 (46.7%)

 Yes

452 (57.6%)

8633 (54.7%)

39763 (53.0%)

48848 (53.3%)

Median OS (95% CI, months)

8.0 (7.0–9.0)

9.0 (8.0–9.0)

8.0 (8.0–8.0)

8.0 (8.0–8.0)

6-month OS rate (95% CI)

56.7% (53.3–60.3)

61.6% (60.8–62.3)

56.9% (56.6–57.3)

57.7% (57.4–58.1)

1-year OS rate (95% CI)

31.3% (28.3–34.8)

32.6% (31.8–33.3)

38.4% (38–38.7)

37.3% (37–37.6)

2-year OS rate (95% CI)

14.6% (12.4–17.3)

13.0% (12.5–13.5)

21.7% (21.4–22)

20.1% (19.9–20.4)

3-year OS rate (95% CI)

8.4% (6.7–10.6)

8.1% (7.7–8.5)

14.6% (14.4–14.9)

13.4% (13.2–13.6)